title: Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions.
abstract: Erythropoiesis-stimulating agents are indicated for the treatment of chemotherapy induced-anemia in cancer patients. Controlled clinical studies have shown that epoetin alfa consistently and significantly increases levels of hemoglobin (Hb), decreases the need for RBC transfusion, and improves the quality of life that is of such importance in cancer patients with a limited life expectancy. The rise achieved in Hb level correlates with an improvement in quality of life. Studies have also demonstrated that earlier initiation of epoetin therapy (i.e., starting treatment at an Hb level of 10-11 g/dl rather than waiting for Hb to fall to <10 g/dl) is associated with a faster achievement of an optimal Hb level, a lower transfusion requirement, and a maintained quality of life.
authors.affiliation: Département d'Oncologie Médicale, Groupe Hospitalier Pitié-Salpétrière, 47 Boulevard de l'Hôpital, 75013 Paris, France. jean-philippe.spano@psl.aphp.fr
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Spano
authors.forename: David
authors.initials: D
authors.lastname: Khayat
mesh_terms: D000740:Anemia / Q000139:chemically induced / Q000628:therapy*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D011994:Recombinant Proteins
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin